Impact of high‐risk prenatal screening results for 22q11.2 deletion syndrome on obstetric and neonatal management: Secondary analysis from the SMART study
Prenatal Diagnosis · 2023-12 · 43 (13) · 1574-1580
DOI: 10.1002/pd.6483 ↗Kurz gefasst
Fachartikel in der Zeitschrift Prenatal Diagnosis, online erschienen am 08.12.2023. Verfasst von Kimberly Martin und 19 weiteren Autor:innen. Beteiligte Einrichtung: Natera Inc., Austin, Texas, USA. Hauptthemen laut MEDLINE: DiGeorge Syndrome, Cell-Free Nucleic Acids. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natera.
Abstract (Originalsprache)
Objective
One goal of prenatal genetic screening is to optimize perinatal care and improve infant outcomes. We sought to determine whether high‐risk cfDNA screening for 22q11.2 deletion syndrome (22q11.2DS) affected prenatal or neonatal management.
Methods
This was a secondary analysis from the SMART study. Patients with high‐risk cfDNA results for 22q11.2DS were compared with the low‐risk cohort for pregnancy characteristics and obstetrical management. To assess differences in neonatal care, we compared high‐risk neonates without prenatal genetic confirmation with a 1:1 matched low‐risk cohort.
Results
Of 18,020 eligible participants enrolled between 2015 and 2019, 38 (0.21%) were high‐risk and 17,982 (99.79%) were low‐risk for 22q11.2DS by cfDNA screening. High‐risk participants had more prenatal diagnostic testing (55.3%; 21/38 vs. 2.0%; 352/17,982, p < 0.001) and fetal echocardiography (76.9%; 10/13 vs. 19.6%; 10/51, p < 0.001). High‐risk newborns without prenatal diagnostic testing had higher rates of neonatal genetic testing (46.2%; 6/13 vs. 0%; 0/51, P < 0.001), echocardiography (30.8%; 4/13 vs. 4.0%; 2/50, p = 0.013), evaluation of calcium levels (46.2%; 6/13 vs. 4.1%; 2/49, P < 0.001) and lymphocyte count (53.8%; 7/13 vs. 15.7%; 8/51, p = 0.008).
Conclusions
High‐risk screening results for 22q11.2DS were associated with higher rates of prenatal and neonatal diagnostic genetic testing and other 22q11.2DS‐specific evaluations. However, these interventions were not universally performed, and >50% of high‐risk infants were discharged without genetic testing, representing possible missed opportunities to improve outcomes for affected individuals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Natera Inc., Austin, Texas, USA.
- Department of Obstetrics, Gynecology and Reproductive Sciences, University of California San Francisco, San Francisco, California, USA.
- The Biostatistics Center, George Washington University, Washington, District of Columbia, USA.
- Ouma Health, Park City, Utah, USA.
- Department of Obstetrics and Gynecology, Rotunda Hospital, Royal College of Surgeons in Ireland, Dublin, Ireland.
- Department of Obstetrics and Gynecology, Columbia Presbyterian Medical Center, New York, New York, USA.
ORCID-Profile: Zachary Demko, Asma Khalil, Bo Jacobson, Pe'er Dar
Förderung
- Natera
Zitieren
APA
Martin, K., Norton, M. E., MacPherson, C., Demko, Z., Egbert, M., Haeri, S., Malone, F., Wapner, R. J., Roman, A. S., Khalil, A., Faro, R., Madankumar, R., Strong, N., Silver, R., Vohra, N., Hyett, J., Kao, C., Hakonarson, H., Jacobson, B., & Dar, P. (2023). Impact of high‐risk prenatal screening results for 22q11.2 deletion syndrome on obstetric and neonatal management: Secondary analysis from the SMART study. Prenatal Diagnosis, 43(13), 1574-1580. https://doi.org/10.1002/pd.6483
Vancouver
Martin K, Norton ME, MacPherson C, Demko Z, Egbert M, Haeri S, et al. Impact of high‐risk prenatal screening results for 22q11.2 deletion syndrome on obstetric and neonatal management: Secondary analysis from the SMART study. Prenatal Diagnosis. 2023;43(13):1574-1580. doi:10.1002/pd.6483
BibTeX
@article{Martin2023,
author = {Martin, Kimberly and Norton, Mary E and MacPherson, Cora and Demko, Zachary and Egbert, Melissa and Haeri, Sina and Malone, Fergal and Wapner, Ronald J and Roman, Ashley S and Khalil, Asma and Faro, Revital and Madankumar, Rajeevi and Strong, Noel and Silver, Robert and Vohra, Nidhi and Hyett, Jon and Kao, Charlly and Hakonarson, Hakon and Jacobson, Bo and Dar, Pe'er},
title = {Impact of high‐risk prenatal screening results for 22q11.2 deletion syndrome on obstetric and neonatal management: Secondary analysis from the SMART study},
journal = {Prenatal Diagnosis},
year = {2023},
volume = {43},
number = {13},
pages = {1574--1580},
doi = {10.1002/pd.6483}
}
EUVIMED